# High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

> **NCT01896271** · PHASE2 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 30 (actual)

## Conditions studied

- Metastatic Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** IL-2
- **RADIATION:** Stereotactic Ablative Body Radiation Therapy

## Key facts

- **NCT ID:** NCT01896271
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-02
- **Primary completion:** 2020-08-25
- **Final completion:** 2021-04-20
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01896271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01896271, "High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01896271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*